Abstract:A major driver for the recent investment surge in bispecific antibody (bsAb) platforms and products is the multitude of distinct mechanisms of action that bsAbs offer compared to a combination of two monoclonal antibodies. Four bsAb products were granted first regulatory approvals in the US or EU during 2023 and the biopharmaceutical industry pipeline is brimming with bsAb candidates across a broad range of therapeutic applications. In previously reported bsAb discovery campaigns, following a hypothesis-based choice of two specific target proteins, selections and screening activities have often been performed in mono-specific formats. The conversion to bispecific modalities has usually been positioned toward the end of the discovery process and has involved small numbers of lead molecules, largely due to challenges in expressing, purifying, and analyzing large numbers of bsAbs. In this review, we discuss emerging strategies to facilitate the production of expanded bsAb panels, focusing particularly upon combinatorial methods to generate bsAb matrices. Such technologies will enable screening in. bispecific formats at earlier stages of discovery campaigns, not only widening the accessible protein space to maximize chances of success, but also advancing empirical bi-target validation activities to assess initial target selection hypotheses.

What problem does this paper attempt to address?

The problem that this paper attempts to solve is to improve the high - throughput production of bispecific antibodies (bsAbs) and their potential applications in the biopharmaceutical discovery workflow. Specifically, the paper focuses on the following points: 1. **Expansion of bsAb panel production**: In the traditional bsAb discovery process, monoclonal antibodies are usually converted into bispecific forms only in the later stages of the discovery process, which limits the molecular diversity that can be tested. The paper discusses emerging strategies, especially combinatorial methods, to generate bsAb matrices, so that bispecific forms can be screened in the early stages of the discovery process, increasing the chances of success and validating the initial target selection hypothesis. 2. **High - throughput production techniques**: In order to achieve large - scale bsAb screening, high - throughput bsAb production methods need to be developed. The paper explores a variety of techniques, including gene integration, cell culture systems and protein engineering solutions, to improve the expression level and purity and ensure consistent quality when handling a large number of samples. 3. **Applicability at different stages**: The paper discusses the applicability of these high - throughput production methods at different stages of bsAb discovery (such as target identification, lead discovery, lead optimization, and early chemical manufacturing and control). For example, in the early stages, lower purity and smaller sample volumes can be tolerated, while in the later stages, highly purified samples are required for detailed characterization. 4. **Requirements for specific formats**: For certain specific bsAb formats (such as IgG - like bsAbs), the geometric structure is crucial for function. The paper discusses how to achieve correct molecular assembly through different chain - pairing techniques (such as HC - HC and HC - LC pairing) and introduces the applications of these techniques in different formats. 5. **Automation and data management**: In order to achieve an end - to - end high - throughput production process, the paper also discusses the integration of automated systems, including steps such as expression vector generation, protein expression, purification, and biophysical validation, and how to ensure the reliability of sample tracking and data storage through software and database management systems. In summary, this paper aims to accelerate the discovery and development process of bispecific antibodies by improving the high - throughput production techniques of bsAbs, thereby improving the efficiency and success rate of new drug research and development.

Facilitating high throughput bispecific antibody production and potential applications within biopharmaceutical discovery workflows

A high throughput bispecific antibody discovery pipeline

Biology Drives the Discovery of Bispecific Antibodies As Innovative Therapeutics.

The present and future of bispecific antibodies for cancer therapy

Bioassay Development for Bispecific Antibodies—Challenges and Opportunities

The renaissance of chemically generated bispecific antibodies

A pivotal decade for bispecific antibodies?

End-To-End Automated Intact Protein Mass Spectrometry for High-Throughput Screening and Characterization of Bispecific and Multispecific Antibodies

Bispecific antibodies: advancing precision oncology

Bispecific Antibodies: From Research to Clinical Application

A Generic Approach for Miniaturized Unbiased High-Throughput Screens of Bispecific Antibodies and Biparatopic Antibody–Drug Conjugates

Developability considerations for bispecific and multispecific antibodies

Clinical Pharmacology Strategies for Bispecific Antibody Development: Learnings from FDA-Approved Bispecific Antibodies in Oncology

Bispecific Antibody (bsab) Construct Formats and Their Application in Cancer Therapy.

Bispecific antibodies in cancer therapy: Target selection and regulatory requirements

An efficient process of generating bispecific antibodies via controlled Fab-arm exchange using culture supernatants

Generation of robust bispecific antibodies through fusion of single-domain antibodies on IgG scaffolds: a comprehensive comparison of formats

Design and engineering of bispecific antibodies: insights and practical considerations

Bispecific Antibodies As a Development Platform for New Concepts and Treatment Strategies

Bispecific antibodies ( bsAbs ) combine the functionality of two antibodies in one molecule . Two bsAb-drugs

General strategies for IgG‐like bispecific antibody purification